1 / 30

Polyps – Where do they come from and what do you do with them?!

Polyps – Where do they come from and what do you do with them?!. Ron G. Landmann, MD Grand Rounds Department of Surgery St. Luke’s-Roosevelt Hospital Center March 21, 2007. Polyps. Cancer epidemiology Definition of the malignant polyp Natural history of adenomatous polyps

esmeralda
Download Presentation

Polyps – Where do they come from and what do you do with them?!

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Polyps – Where do they come from and what do you do with them?! Ron G. Landmann, MD Grand Rounds Department of Surgery St. Luke’s-Roosevelt Hospital Center March 21, 2007

  2. Polyps • Cancer epidemiology • Definition of the malignant polyp • Natural history of adenomatous polyps • Biology of polyps • The anatomy of the polyp • Correlations with Malignancy • Endoscopic polypectomy alone??? • Special considerations * No discussion of technique

  3. Colorectal Cancer – Epidemiology • Incidence: Approx. 150,000 cases/year • Deaths: Approx. 50,000 deaths/year • At diagnosis • 10% in situ disease • 30% local disease • 30% regional disease • 30% distant disease • 5 year survival, all patients: 50% • local - 90% • regional - 60% • distant - 5% U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2003 Incidence and Mortality (preliminary data). Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2006.

  4. Incidence/Prevalence of Polyps • Adenomatous polyps • 30% of Western population • Most cancers arise from polyps • *excludes syndromes

  5. Carcinoma in situ vs. cancer •  Think • Carcinoma in situ = high grade dysplasia • Carcinoma in situ≠ cancer Histology Colorectal cancer is defined by invasion of/through muscularis mucosa

  6. Histology • Colorectal cancer is defined by invasion of muscularis mucosa • Lymphatics are located in submucosa Genetic model of colorectal tumorigenesis

  7. Colon Cancer Staging

  8. Colon Cancer Staging

  9. Relationship Between TNM Stage and Survival in Colorectal Carcinoma CA Cancer J Clin 2004;54;295-308

  10. Treatment of CRC • Polypectomy • Colonic Resection • Treatment depends on the risk of lymph node metastasis. •  Pathology is key! • Colorectal cancer is defined by invasion of muscularis mucosa • Lymphatics are located in submucosa

  11. Incidence of malignant polyps • Definition • Malignant polyps or T1 lesions (limited to the submucosa) • Represent 5% of all adenomas • Colonoscopy polypectomy series: 2 – 12% • Colorectal resection series: 4 – 9%

  12. Haggitt Level (1985)Classification of polyps with invasive cancer Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinoma arising in adenomas: Implications for lesions removed by endoscopic polypectomy. Gastroenterology 89:328-36, 1985, p 330. Villuous/sessile (flat) polyps with invasive cancer are by definition Haggitt 4.

  13. Sessile Polyps Kudo, 1993 • Risk of lymph node metastasis in each sessile lesion is not the same • Haggitt’s: no detail for sessile lesions • Classification of submucosal invasion: • Sm1—Invasion into the upper third of the submucosa • Sm2—Invasion into the middle third of the submucosa • Sm3—Invasion into the lower third of the submucosa • High rate of LN metastasis: 12-25%

  14. Sm system • Able to determine Sm1, Sm2, Sm3 in 97% of cases • Haggitt Level 1, 2, 3 = Sm1 • Haggitt Level 4 = Sm1, Sm2, or Sm3 • Endoscopist must properly resect and prepare specimen • Pathologist must properly section and examine all layers

  15. Correlations with MalignancyMorphology

  16. Correlations with MalignancyGrade

  17. Correlations with MalignancySize Muto, 1975

  18. Correlations with MalignancySize Muto, 1975 Nusco, 1997

  19. Relationship betweenSize and Morphology St. Mark’s Hospital Data

  20. Increased risk of LN Metastasis • Unfavorable pathologic features of malignant CR polyps • Poor differentiation (only on univariate) • Lymphovascular invasion (P < 0.009) • Invasion below submucosa (Haggitt Level 4) • Depth of invasion in Sm3 (P < 0.001) • Site in lower 1/3 of the rectum (P < 0.001) • Positive resection margin (< 1 mm or 1 HPF) • Not really – this is inadequate treatment, not an adverse risk factor! P-values from Nascimbeni et al. N = 353 T1 colorectal sessile lesions

  21. Management of Pedunculated Malignant Polyps • Haggitt Level 1, 2, 3 • Complete excision or snaring • Risk of LN metastasis < 1% • Haggitt Level 4 • Treat as sessile lesions

  22. Management of Sessile Malignant Polyps • < 2cm in diameter • Adequate snare in one piece via colonoscopy • Requires microscopic free margin of at least 2mm • Piecemeal removal • Requires further excision/follow-up or resection • High risk factors (LVI, Sm3, distal 1/3 rectum) • Oncologic resection • Full thickness transanal excision

  23. Lesions amenable to colonoscopic polypectomy • Pedunculated or sessile < 2cm • Well/moderately differentiated • No lymphovascular invasion • Haggitt Level 1-3 or Sm1 • Close follow-up available • Endoscopically complete excision • Negative resection margins (2mm)

  24. Criteria for Treatment of Malignant CR Polyps by Polypectomy Alone • Determined by risk of metastasis • Low risk of Lymph Node Metastasis • Pedunculated • Haggitt Level 1, 2, 3 • Level 4 Sm1, Sm2 • Sessile • Sm1, Sm2 • High risk of Lymph Node Metastasis • Lower 1/3 of the submucosa (Sm3) • LVI • Distal 1/3 of rectum

  25. Malignant Colorectal Polyps that Should have an Oncologic Bowel Resection • Lesions in colon • Pedunculated Haggitt Level 4 with invasion into distal third of submucosa (Sm3) or LVI • Sessile lesions removed with margin < 2mm • Sessile lesions removed piecemeal • Sessile lesions with depth of invasion into distal third of submucosa (Sm3) • Sessile lesions with LVI • Lesions in middle third and upper third rectum • Same as lesions in colon • Lesions in distal third rectum • Pedunculated Haggitt Level 4 with invasion into distal third of submucosa (Sm3) or pedunculated lesions with LVI • All sessile lesions

  26. Why not just resect anyway?!

  27. What if ??? • What if it’s clipped in ½? • Pedunculated • Repeat endoscopy. • Require good resection with margin (2mm) • Sessile • Requires operative oncologic resection (even if Sm1, Sm2) • Unable to determine exact pathologic depth • What if it’s shredded by forceps? • Requires operative oncologic resection • What if it’s a very small lesion? • Requires marking/tattoo CIRCUMFERENTIALLY • What if it’s carcinoma in situ? • It’s not cancer. This is high grade dysplasia. Requires close follow-up. • Unless, • poor margins: repeat endoscopy with good margins • Piecemeal resection: discussion with pathologist and patient • What if it’s a large, non-endoscopically resectable polyp? • Repeat endoscopy (2nd MD?) • Oncologic resection

  28. Other considerations… • When in doubt • Repeat colonoscopy (endoscopy) • Personally review pathology • Get a second opinion • Have a frank discussion with patient

  29. Polyps • Natural history of adenomatous polyps • Biology of polyps • Cancer epidemiology • The anatomy of the polyp • Correlations with Malignancy • Endoscopic polypectomy alone??? • Special considerations • Indications for Polypectomy • What if it’s clipped in ½ • What if it’s shredded by forceps? • Pathology… • Marking/tattoo • Chances of Malignancy by histopath and size/morphology • * NO technique **

More Related